| Document |
Document Title |
|
WO/2023/023469A1 |
Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.
|
|
WO/2023/020412A1 |
The present invention relates to a sulfonylurea compound represented by formula I, a preparation method therefore, and an application thereof. The compound of the present invention has soluble epoxide hydrolase (sEH) inhibitory activity ...
|
|
WO/2023/021895A1 |
Provided is an ionic liquid that can be used for semiconductor manufacturing and that has a low metal ion content. This ionic liquid comprises cations and anions and contains, each by not more than 100 ppb, metal ions of 16 elements in...
|
|
WO/2023/018217A1 |
The present invention relates to a method for synthesizing bilirubin, and more specifically to a method for chemically synthesizing, for the first time, bilirubin and pegylated bilirubin, which are effectively used for medicines and the ...
|
|
WO/2023/018960A1 |
The invention provides novel improved methods for preparing indolinobenzodiazepine dimer compounds and their synthetic precursors.
|
|
WO/2023/018215A1 |
The present invention relates to a method for synthesizing bilirubin. The present invention relates to a first method for chemically synthesizing bilirubin and PEGylated bilirubin, which are usefully used in a medicinal product or the li...
|
|
WO/2023/011938A1 |
The present invention relates to specific bismaleimide compounds, curable compositions comprising at least one of these bismaleimides and at least one specific polyimide. Furthermore, the present invention refers to a process for the man...
|
|
WO/2023/014793A1 |
The disclosure relates to synthetic methods for producing polyamides, for example pyrrole and imidazole containing polyamides of Formula (I) or (II), or a pharmaceutically acceptable salts thereof. These polyamides bind genes having expa...
|
|
WO/2023/014758A1 |
Provided are compounds of Formula (I), Formula (la), Formula (lb), and their use in methods of inhibiting the replication of noroviruses and coronaviruses in a biological sample or patient, of reducing the amount of noroviruses or corona...
|
|
WO/2023/014768A1 |
Compounds of Formula I, Formula II, and Formula III and the pharmaceutically acceptable salts thereof are disclosed. The variables R1-10 are disclosed herein. The compounds are useful for treating central nervous system disorders, especi...
|
|
WO/2023/008644A1 |
The present invention relates to an organic compound and an organic light-emitting device comprising same, the organic compound being employed in an optical efficiency improvement layer, which is provided in an organic light-emitting dev...
|
|
WO/2023/004687A1 |
Provided by the present invention is an unnatural amino acid, which is a compound having a structure as shown in formula (I) or an enantiomer thereof. Further provided by the present invention is an application of the unnatural amino aci...
|
|
WO/2023/009521A1 |
This disclosure pertains to the preparation of bifunctional compounds (e.g., Compound 1), intermediates in the preparation of such compounds, and preparation of such intermediates. Compound 1
|
|
WO/2023/006645A1 |
The invention relates to novel compounds having the general formula (I) wherein R1, R2, R3, R4, R5, R6, R7, W, m and n are as described herein, composition including the compounds and methods of using the compounds.
|
|
WO/2023/001088A1 |
The present invention discloses a preparation method of 3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride and (S) -3- (2, 2, 2-trifluoroethyl) pyrrolidine hydrochloride.
|
|
WO/2023/284611A1 |
ROS-responsive prodrugs and methods of making thereof are disclosed. These prodrugs can contain two captopril moieties and one cinnamaldehyde moiety that are linked by a thioacetal linking moiety; upon cleavage of the thioacetal linking ...
|
|
WO/2023/285787A1 |
A process for preparing a compound of formula I, or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula I.
|
|
WO/2023/285072A1 |
The present invention relates to compound of formula (I), a diastereomer, enantiomer, crystal or co-crystal thereof, or a pharmaceutically acceptable salt, or mixture thereof. The present invention also relates to pharmaceutical composit...
|
|
WO/2023/287938A1 |
The present disclosure encompasses solid state forms of Amcenestrant, in embodiments crystalline polymorphs of Amcenestrant, processes for preparation thereof, and pharmaceutical compositions thereof.
|
|
WO/2023/285788A1 |
A process for preparing a compound of formula (I), or a salt thereof, as defined herein. Also, compounds of formula I and intermediate compounds useful in the preparation of a compound of formula (I).
|
|
WO/2023/280155A1 |
Disclosed are a compound of formula (I), wherein the variables are defined in the specification, a pharmaceutical composition containing the same, and a method and a use of the compound or composition in the treatment of a PCSK9-mediated...
|
|
WO/2023/281421A1 |
Hydrofluoroolefin amine compounds are represented by the following general formula (I): 5 (Rf 2-)(Rf 3CF2-)N-CH=CF-Rf 1 Formula I where Rf 1 is a linear, branched, or cyclic fluoroalkyl group containing 1-5 carbon atoms and may contain u...
|
|
WO/2023/280288A1 |
A new pyrrole sulfonyl derivative and a preparation method therefor, and a pharmaceutical composition containing the derivative and a use thereof in preparation of a drug. Specifically, the structure of the pyrrole sulfonyl derivative is...
|
|
WO/2023/280290A1 |
The present invention relates to a class of pyrrole sulfonyl derivatives, a preparation method therefor, a pharmaceutical composition containing same, and the use thereof in the preparation of a drug. Specifically, the present invention ...
|
|
WO/2023/280293A1 |
The present invention relates to a pyrrole sulfonyl derivative, a preparation method therefor, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, especially as a gastric acid secretion inhib...
|
|
WO/2023/274869A1 |
The invention relates to new herbicidally active 3-(4-(E)-alkenyl-phenyl)-3-pyrrolino-2-ones according to general formula (I) or to agrochemically acceptable salts thereof and to their use for controlling weeds and weed grasses in crops ...
|
|
WO/2023/277605A1 |
The present invention provides a novel compound for a capping layer and an organic light-emitting device containing same.
|
|
WO/2023/278300A1 |
The invention features solid dosage forms of N-1-pyrrolidine-N-5-(3-trifluoromethoxy)phenyl biguanide, or a pharmaceutically acceptable salt thereof, where the solid dosage form includes an enteric coating and uses thereof.
|
|
WO/2022/268520A1 |
The invention relates to the use of substituted pyrrolidinones of general formula (I), or their salts, wherein the groups in general formula (I) are defined as indicated in the description, for increasing the stress tolerance of plants w...
|
|
WO/2022/271970A1 |
Disclosed herein, inter alia, are modified nucleotides and methods of using the same in nucleic acid sequencing reactions.
|
|
WO/2022/268814A1 |
The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminogua
nidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.
|
|
WO/2022/266753A1 |
There are provided conjugates of Formula (V) wherein R1 is a triantennary targeting moiety comprising N-acetyl galactosamine and R2 is a bioactive agent which is preferably an oligonucleotide, as well as pharmaceutical compositions and m...
|
|
WO/2022/268825A1 |
The disclosure relates to oral formulations for gastric delivery of a pharmaceutically acceptable salt of a phenyl pyrrole aminoguanidine compound.
|
|
WO/2022/263829A1 |
The invention relates to compounds or salts of Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (II) and pharmaceutical compositions containing these compounds. The compounds may be inducers of α1-antitrypsin (A1AT), ...
|
|
WO/2022/266082A1 |
Disclosed is a method of preparing diroximel fumarate represented by the following structural formula (I) The method comprises reacting ethylene carbonate with succinimide to form a hydroxyethyl succinimide intermediate; and reacting the...
|
|
WO/2022/266363A1 |
Provided herein are compounds of Formula (I), their pharmaceutically acceptable salts, and their pharmaceutical compositions: wherein R1, R2, R3a, R3b, R4, R5, and A are defined in the present disclosure. The compounds are potent inhibit...
|
|
WO/2022/264971A1 |
The present disclosure provides a method for evaluating the quality of sperm. The present disclosure provides a method for evaluating the quality of sperm, said method comprising: a step for obtaining a mixed solution by mixing a sperm...
|
|
WO/2022/262657A1 |
The present invention relates to an N-substituted phenylsulfonamide compound and a use thereof. Specifically, the present invention provides a compound represented by formula I, or an optical isomer thereof, or a racemate thereof, or a p...
|
|
WO/2022/261473A1 |
The application relates to compounds of Formula (I) and (III), their pharmaceutically acceptable salts, and their pharmaceutical compositions. The compounds are potent inhibitors of the main protease (Mpro) of severe acute respiratory sy...
|
|
WO/2022/259266A1 |
The present invention relates to functionalized Maleimides and Isomaleimides of general Formula (I) and a process for the preparation thereof, involving [3+2] annulation of α, β-5 unsaturated aldehydes with carbamoyl alkylates via an e...
|
|
WO/2022/256482A1 |
Provided are methods for making crystalline forms of (S)-(-)-amisulpride and (R)-(+)-amisulpride. Also provided are pharmaceutical compositions comprising the crystalline forms of (S)-(-)-amisulpride and (R)-(+)-amisulpride and methods o...
|
|
WO/2022/256267A1 |
Provided are methods of treating or preventing Raynaud's, comprising prescribing and/or administering to an individual in need thereof 3-methoxy-N-[3-(2-methylpyrazol-3-yl)-4-(2-morpholin-4-yleth
oxy)phenyl]benzamide (Compound 1), or a p...
|
|
WO/2022/256434A1 |
Provided herein, inter alia, are compounds, pharmaceutical compositions and methods related to the treatment of viral infections caused by coronavirus or enterovirus. Provided herein are compounds of Formula (I), (II) and (III) and metho...
|
|
WO/2022/254027A1 |
The present invention relates to a compound of formula (I), or a tautomer, a stereoisomer, a hydrate, a solvate, a polymorph, a prodrug, an isotope, or a co-crystal thereof, or a pharmaceutically acceptable salt thereof, wherein R1, R2, ...
|
|
WO/2022/247755A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol andpolymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucl...
|
|
WO/2022/251615A1 |
Disclosed are bis-amide inhibitors of SARS-CoV-2 (CO VID), and methods of using them to treat a severe acute respiratory syndrome.
|
|
WO/2022/251280A1 |
Disclosed herein are compounds selective for JAK1, pharmaceutical compositions comprising said compounds, and methods of using said compounds.
|
|
WO/2022/241513A1 |
The present application relates to metal-organic framework (MOF) encapsulation of lipid-nucleic acid formulations. The present application discloses methods for stabilizing lipid-nucleic acid formulations and provides MOF encapsulated li...
|
|
WO/2022/242278A1 |
A method for synthesizing an intermediate of upadacitinib, comprising: (1) compound formula 1 undergoes an epoxidation reaction, an addition reaction, and a protection reaction to obtain compound formula 4; compound formula 4 reacts with...
|
|
WO/2022/243238A1 |
The invention relates to a system (10) for cleaning recovered NMP from a lithium-ion battery production, comprising a first column (16) for separating low-boiling impurities, said first column having a feed (16a) for the recovered NMP in...
|
